|
Post by mnholdem on Feb 6, 2018 15:47:35 GMT -5
Former Chief Scientific and Medical Officer of the American Diabetes Association - that is the position that oversees the group that updates the ADA Diabetes Standard of Care. Dr. Kendall may be quite influential with that group.
|
|
|
Post by matt on Feb 6, 2018 16:33:21 GMT -5
I dunno, this guy's education is centered in Minnesota. Perhaps he's wily, though. After spending all those winters in Minneapolis, he was just happy to get hired by a company in California. I have made a few trips to the Univ of Minnesota in Jan and Feb, and it is absolutely brutal up there this time of year. On the other hand, it is one of the most underrated medical schools in the country. Some of the work they do there is absolutely top notch, and a lot of it is in diabetes. They tend to be a bit more device focused than most, which is logical given the proximity to Medtronic headquarters, but they also do some interesting work on transgenic animals.
|
|
|
Post by kc on Feb 6, 2018 16:48:00 GMT -5
He has been Living in Indy since 2011
|
|
|
Post by babaoriley on Feb 6, 2018 17:03:45 GMT -5
I dunno, this guy's education is centered in Minnesota. Perhaps he's wily, though. After spending all those winters in Minneapolis, he was just happy to get hired by a company in California. I have made a few trips to the Univ of Minnesota in Jan and Feb, and it is absolutely brutal up there this time of year. On the other hand, it is one of the most underrated medical schools in the country. Some of the work they do there is absolutely top notch, and a lot of it is in diabetes. They tend to be a bit more device focused than most, which is logical given the proximity to Medtronic headquarters, but they also do some interesting work on transgenic animals.Oh, great, just what we need, another protected class!
|
|
|
Post by babaoriley on Feb 6, 2018 17:07:10 GMT -5
I dunno, this guy's education is centered in Minnesota. Perhaps he's wily, though. ...and I suppose that you also think that Minnesota's Mayo Clinic is just an urgent care center? "Gimme Ham on five, hold the Mayo." What I like about him, in addition to his unbelievably good credentials, is that he isn't ancient, so this isn't an emeritus type position. This is a real job, into which he can pour some real energy. Rochester's in Minnesota? Not NY? Gosh, no wonder I could never find that clinic there.
|
|
|
Post by seanismorris on Feb 6, 2018 17:42:17 GMT -5
After spending all those winters in Minneapolis, he was just happy to get hired by a company in California. I have made a few trips to the Univ of Minnesota in Jan and Feb, and it is absolutely brutal up there this time of year. On the other hand, it is one of the most underrated medical schools in the country. Some of the work they do there is absolutely top notch, and a lot of it is in diabetes. They tend to be a bit more device focused than most, which is logical given the proximity to Medtronic headquarters, but they also do some interesting work on transgenic animals.Oh, great, just what we need, another protected class! Well... Glowing mice are pretty cool!
|
|
|
Post by falconquest on Feb 6, 2018 18:02:20 GMT -5
I just can't help to think that bringing on David Kendall as CMO with all his lifelong diabetes experience possibly points to MNKD selling off technosphere and concentrating fully on Afrezza. Really? Our purveyor of partnerships, Locust Walk, has not been able to establish a partner for Technosphere so what do you think it's worth? Wait a minute, let's see what kind of change I have in my pocket here....
|
|
|
Post by kc on Feb 6, 2018 18:05:12 GMT -5
I think that either Mike did a great job of hiring David Kendall or there is more excitement in the near term future for all of us.
Kendall is a player and he was very important to Lilly. If you go to the Lilly web site and do a search for his name he appears on many of the press releases regarding Lilly diabetes products.
investor.lilly.com/search.cfm?method=and&keyword=David+Kendall
Below are a few excerpts of what I found:
DAVID KENDALL
2017 investor.lilly.com/releasedetail.cfm?ReleaseID=1040017 "Cardiovascular disease remains the leading cause of death in people with type 2 diabetes and contributes significantly to the burden of diabetes care," said David Kendall, M.D., distinguished medical fellow, Lilly Diabetes. "The results presented at EASD add further evidence of the benefit Jardiance can provide to adults with type 2 diabetes with different background blood sugar control."
2016 investor.lilly.com/releasedetail.cfm?releaseid=975348
"MOSA1c provides a broad view of clinical, psychosocial and health system factors available and will serve to create a greater understanding of needs within each system," said David Kendall, vice president, Global Medical Affairs, Lilly Diabetes. "These data can help us better understand why so many patients using insulin are not achieving glycemic goals. We know that this is a complex multi-factorial issue and it is critical to take into account the specific cultural, social and individual barriers people with diabetes face when adjustment of insulin therapy is considered most useful."
2016 investor.lilly.com/releasedetail.cfm?releaseid=1004325
"Lilly and Boehringer Ingelheim are proud to bring another proven effective diabetes treatment choice to people who may need a long-acting insulin to help control their blood sugar," said David Kendall, M.D., vice president, Global Medical Affairs, Lilly Diabetes. "We know that starting insulin can be a challenging experience for some people with type 2 diabetes. As part of our continuing commitment to the diabetes community, we are expanding our educational resources."
2016 investor.lilly.com/releasedetail.cfm?ReleaseID=953190 "We at Lilly Diabetes take great pride in our support of diabetes camps. For more than a decade, many individuals have reported positive experiences and shared how important the camp experience is for children with diabetes as they learn to care for themselves," said David Kendall, MD, vice president of medical affairs, Lilly Diabetes. "These exciting survey results help confirm that campers are having a positive experience. We couldn't be happier that our donations to the Association's Campership program are having such an impact."
2015 investor.lilly.com/releasedetail.cfm?releaseid=916577 "We are honored to continue partnering with IDF on Life for a Child," said David Kendall, M.D., vice president for medical affairs, Lilly Diabetes. "Through this new commitment of insulin, we will build on the substantial impact that Life for a Child has had in communities with very significant needs across the globe. Our commitment to these children will help them manage their diabetes and have much brighter futures."
2015 investor.lilly.com/releasedetail.cfm?releaseid=914967 INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- New clinical data demonstrating the range of treatment options represented in Lilly's (NYSE: LLY) diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. These presentations reflect Lilly's efforts to enhance scientific knowledge and improve current approaches to diabetes management. Thirty-five of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes alliance. "The Scientific Sessions are an important opportunity for researchers and healthcare and industry professionals to come together and share learnings and advances in diabetes care," said David Kendall, M.D., vice president of Medical Affairs, Lilly Diabetes. "We look forward to communicating significant new data that showcase the full range of our diabetes portfolio."
The relationship with Lilly and Kendall goes back to 2007 when Kendall worked for Amylin Pharmaceutical and their joint venture work on Byetta.
2007 investor.lilly.com/releasedetail.cfm?releaseid=250792 "The sustained improvements in blood glucose control and the secondary benefits of progressive weight loss seen with BYETTA are well documented," said David Kendall, Executive Director, Medical Affairs, Amylin Pharmaceuticals, Inc. "These studies document that BYETTA may have additional and important effects on cardiovascular disease risk factors providing interesting areas for further study, including additional metabolic advantages of weight loss in people with diabetes."
I am probably letting my mind and fantasy of the future getting the best of me but perhaps there is a bridge to the future of MannKind in the comments made by Lilly CEO at JPM 2018.
www.lilly.com/6-thoughts-from-dave-ricks-jpm-talk
Key priorities for Lilly moving forward: 1.Launch with excellence, introducing our newest set of medicines around the world. 2.Reload our pipeline, with promising opportunities in our labs and outside to take the place of an exciting graduating class of new medicines.
|
|
|
Post by falconquest on Feb 6, 2018 18:09:45 GMT -5
I think that either Mike did a great job of hiring David Kendall or there is more excitement in the near term future for all of us.
Kendall is a player and he was very important to Lilly. If you go to the Lilly web site and do a search for his name he appears on many of the press releases regarding Lilly diabetes products.
investor.lilly.com/search.cfm?method=and&keyword=David+Kendall
Below are a few excerpts of what I found:
DAVID KENDALL
2017 investor.lilly.com/releasedetail.cfm?ReleaseID=1040017 "Cardiovascular disease remains the leading cause of death in people with type 2 diabetes and contributes significantly to the burden of diabetes care," said David Kendall, M.D., distinguished medical fellow, Lilly Diabetes. "The results presented at EASD add further evidence of the benefit Jardiance can provide to adults with type 2 diabetes with different background blood sugar control."
2016 investor.lilly.com/releasedetail.cfm?releaseid=975348
"MOSA1c provides a broad view of clinical, psychosocial and health system factors available and will serve to create a greater understanding of needs within each system," said David Kendall, vice president, Global Medical Affairs, Lilly Diabetes. "These data can help us better understand why so many patients using insulin are not achieving glycemic goals. We know that this is a complex multi-factorial issue and it is critical to take into account the specific cultural, social and individual barriers people with diabetes face when adjustment of insulin therapy is considered most useful."
2016 investor.lilly.com/releasedetail.cfm?releaseid=1004325
"Lilly and Boehringer Ingelheim are proud to bring another proven effective diabetes treatment choice to people who may need a long-acting insulin to help control their blood sugar," said David Kendall, M.D., vice president, Global Medical Affairs, Lilly Diabetes. "We know that starting insulin can be a challenging experience for some people with type 2 diabetes. As part of our continuing commitment to the diabetes community, we are expanding our educational resources."
2016 investor.lilly.com/releasedetail.cfm?ReleaseID=953190 "We at Lilly Diabetes take great pride in our support of diabetes camps. For more than a decade, many individuals have reported positive experiences and shared how important the camp experience is for children with diabetes as they learn to care for themselves," said David Kendall, MD, vice president of medical affairs, Lilly Diabetes. "These exciting survey results help confirm that campers are having a positive experience. We couldn't be happier that our donations to the Association's Campership program are having such an impact."
2015 investor.lilly.com/releasedetail.cfm?releaseid=916577 "We are honored to continue partnering with IDF on Life for a Child," said David Kendall, M.D., vice president for medical affairs, Lilly Diabetes. "Through this new commitment of insulin, we will build on the substantial impact that Life for a Child has had in communities with very significant needs across the globe. Our commitment to these children will help them manage their diabetes and have much brighter futures."
2015 investor.lilly.com/releasedetail.cfm?releaseid=914967 INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- New clinical data demonstrating the range of treatment options represented in Lilly's (NYSE: LLY) diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. These presentations reflect Lilly's efforts to enhance scientific knowledge and improve current approaches to diabetes management. Thirty-five of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes alliance. "The Scientific Sessions are an important opportunity for researchers and healthcare and industry professionals to come together and share learnings and advances in diabetes care," said David Kendall, M.D., vice president of Medical Affairs, Lilly Diabetes. "We look forward to communicating significant new data that showcase the full range of our diabetes portfolio."
The relationship with Lilly and Kendall goes back to 2007 when Kendall worked for Amylin Pharmaceutical and their joint venture work on Byetta.
2007 investor.lilly.com/releasedetail.cfm?releaseid=250792 "The sustained improvements in blood glucose control and the secondary benefits of progressive weight loss seen with BYETTA are well documented," said David Kendall, Executive Director, Medical Affairs, Amylin Pharmaceuticals, Inc. "These studies document that BYETTA may have additional and important effects on cardiovascular disease risk factors providing interesting areas for further study, including additional metabolic advantages of weight loss in people with diabetes."
Sooo, where have they been prior to this? Why would they all of a sudden be a player? It's not as though any fundamentals have changed at Mannkind.
|
|
|
Post by sportsrancho on Feb 6, 2018 18:23:32 GMT -5
C raig Dean@ Michael Kovacocy think any chance this article from a week ago about Lilly having 9 billion from the new tax plan to spend on acquisitions and partnerships And the new hire today from Lilly is associated? Might be nothing but interesting regardless. Michael Kovacocy
Craig Dean that is some good sleuthing and interesting. I can't comment with certainty on speculation, and if I did know anything specific on this point, I wouldn't be able to comment. So it is clear that I will just have to defer to you and say that it is certainly plausible, why not? Michael Kovacocy
I would say this. And it isn't rocket science. Mike the CEO continues to deliver what he promised, and is ticking off all the boxes on the company's to do list. This is public info, the list is on loads of presentations, etc. And there are now just a few tick boxes left on the list, and they are biggies. One relating to the subject you have mentioned above. So if I were a betting man, I would expect material news on this point sooner than later. And there is nothing to say that your speculation has any more or less merit than that of others with less optimistic views on the company. I would even be so inclined to say that your thesis makes sense - not so much just for Lilly, but a whole swath of players who might wish to cosy up to MNKD. So the general thrust of your thesis makes sense. Might not be the right company, but makes sense. Holy moly!
|
|
|
Post by sayhey24 on Feb 6, 2018 18:38:51 GMT -5
So what are you saying?
You don't think this guy was desperate for a job and needed a pay check? I found his PR comments being all about afrezza being interesting and exciting. Does a guy with his background who is an expert in diabetes and insulin, knows everyone who is anyone in the diabetes world come to a company which is about to fail? Man, this guy really must be desperate:)
|
|
|
Post by kc on Feb 6, 2018 18:39:25 GMT -5
|
|
|
Post by sayhey24 on Feb 6, 2018 18:51:20 GMT -5
OK, what are you seeing on these slides aside from afrezza obsoleting most of their developments?
|
|
|
Post by gamblerjag on Feb 6, 2018 19:05:12 GMT -5
maybe out of scope is now "in scope".
|
|
|
Post by pengiep on Feb 6, 2018 19:23:40 GMT -5
years ago, back when it was so hard nobody else could do it, I made green moths.
|
|